Effects of Oligofructose and Barley on Satiety and Energy Intake
NCT ID: NCT00776256
Last Updated: 2008-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2007-02-28
2007-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: To test the effect of FOS, BG, or their combination in bars on appetite ratings and food intake during 2 consecutive days.
Design: In a 4-way balanced order cross-over double-blind design, 21 healthy volunteers (mean BMI 25.9 kg/m2) received a meal replacement bar at 09.00h and an ad libitum lunch at 13.00h on 2 consecutive days. On day 1 only, subjects consumed a second (identical) bar at 17.00h and a fixed snack at 19.00h. The control bar contained 0.3g BG (control, from 6.8 g oats), vs equi-caloric bar formulations containing an additional: 1) 0.9 g BG (from 8.0g barley), 2) 8g FOS, or 3) 0.9 g BG + 8g FOS. Appetite scores and subsequent ad libitum test meal intakes were measured. Bar viscosities were determined under simulated gastric conditions. Results were analyzed using ANCOVA.
Results: Addition of BG, FOS or their combination did not affect appetite ratings or food intake, although addition of BG to the bar doubled apparent gastric viscosity (841 vs 351 mPa.s).
Conclusions: BG, FOS or their combination in bars at these levels do not improve appetite control when consumed on 2 consecutive days. Efficacy might be increased by a longer exposure period, increasing the BG content, or a form of BG that generates even higher gastric viscosity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
effect of beta-glucan
beta-glucan and fructooligosaccharide
1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
2
effect of fructo-oligosaccharide
beta-glucan and fructooligosaccharide
1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
3
effect of beta-glucan and fructooligosaccharide
beta-glucan and fructooligosaccharide
1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
4
no beta-glucan nor fructooligosaccharide
beta-glucan and fructooligosaccharide
1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
beta-glucan and fructooligosaccharide
1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Quetelet-Index (BMI) from 21 till 32 kg/m2 inclusive
* Apparently healthy: measured by questionnaire: no reported current or previous metabolic diseases or chronic gastrointestinal disorders
* Reported dietary habits: no medically prescribed diet, no slimming diet, used to eat 3 meals a day, no vegetarian, macro-biotic or biologic dynamic food habits
* No Fibre supplements (only once a day)
* No blood donations during the study.
* Reported intense sporting activities less than 10h/w
* Reported alcohol consumption less than 21 units/w (female volunteers) or less than 28 units/w (male volunteers)
* Having a General Practitioner
* Informed consent signed
* Recruitment form filled out
Exclusion Criteria
* Dislike, allergy/intolerance or not known with the foods of the ad libitum meal
* Possible eating disorder (measured by SCOFF questionnaire)
* High or very high restrained eaters (measured by questionnaire) (men with BMI \< 27: restraint score \> 2.37, men with BMI less than 27: restraint score \> 3.04, women with BMI \< 26: restraint score \> 3.24, women with BMI less than 26: restraint score \> 3.41)
* Reported medical treatment that may affect eating habits/satiety
* Reported intolerance or allergy to test products
* Women reported lactating (or lactating \< 6 weeks ago), pregnant (or pregnant \< 3 months ago) or wish to become pregnant during the study
* Reported weight loss/gain (10%) in the last six month before the trial
* Reported participation in another biomedical trial 1 month before the start of the study
* Reported working on late turns -
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Unilever R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Unilever R&D
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward Haddeman
Role: STUDY_DIRECTOR
Unilever R&D
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unilever R&D Vlaardingen
Vlaardingen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Peters HP, Boers HM, Haddeman E, Melnikov SM, Qvyjt F. No effect of added beta-glucan or of fructooligosaccharide on appetite or energy intake. Am J Clin Nutr. 2009 Jan;89(1):58-63. doi: 10.3945/ajcn.2008.26701. Epub 2008 Dec 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07002V
Identifier Type: -
Identifier Source: org_study_id